Welsh, Kaeli A https://orcid.org/0000-0003-0530-4436
Bolhuis, Derek L https://orcid.org/0000-0002-9062-9739
Nederstigt, Anneroos E https://orcid.org/0000-0002-3695-3677
Boyer, Joshua
Temple, Brenda R S
Bonacci, Thomas
Gu, Li https://orcid.org/0000-0001-7044-6444
Ordureau, Alban https://orcid.org/0000-0002-4924-8520
Harper, J Wade
Steimel, Joshua P
Zhang, Qi
Emanuele, Michael J https://orcid.org/0000-0003-4104-7449
Harrison, Joseph S https://orcid.org/0000-0002-2118-6524
Brown, Nicholas G https://orcid.org/0000-0002-6141-0164
Funding for this research was provided by:
HHS | NIH | National Institute of General Medical Sciences (T32GM135095)
HHS | NIH | National Institute of General Medical Sciences (R01GM120309)
HHS | NIH | National Institute of General Medical Sciences (R35GM128855)
HHS | NIH | National Institute of General Medical Sciences (T32GM008570)
HHS | NIH | National Institute on Aging (R01AG011085)
American Cancer Society (RSG‐18‐220‐01‐TBG)
Article History
Received: 26 May 2021
Revised: 22 November 2021
Accepted: 25 November 2021
First Online: 23 December 2021
Conflict of interest
: J.W.H. is a consultant and founder of Caraway Therapeutics and is a founding advisory board member of Interline Therapeutics.